Successful multimodality treatment of recalcitrant necrobiotic xanthogranuloma using electron beam radiation and intravenous immunoglobulin

Nambudiri, Vinod E.; McLaughlin, C.; Lo, Theodore C.M.; Zembowicz, Artur; Moschella, Samuel L.

doi:10.1111/ced.12719

Cited by 8 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic therapies are not available, thus surgery should be applied as far as possible [9]. The necrobiotic xanthogranuloma (NXG) has occasionally been described in adults in association with paraproteinemia, monoclonal gammopathy or multiple myeloma [81,149], it is not described in children or adolescents.…”

Section: General Remarks and Clinical Presentationmentioning

confidence: 99%

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

Rare histiocytoses, also called non-Langerhans cell histiocytoses, include all proliferative disorders of histiocytes, macrophages and dendritic cells that are not classified as Langerhans cell histiocytosis (LCH) and do not belong to the hemophagocytic lymphohistiocytosis (HLH) group of diseases. Thus, the term includes numerous benign or malignant, localized or systemic, adult or pediatric diseases. The classification of the histiocytic disorders has been revised several times. Here, we follow the classification recently published by Jean Francois Emile and an international expert panel, defining subgroups of histiocytoses described as L-Group, C-Group, M-Group, R-Group, and H-Group, which stands for LCH-like, cutaneous or mucocutaneous, malignant, Rosai-Dorfman-Disease like and HLH like. Some of the diseases have an excellent prognosis after resection or even disappear spontanously, others progress rapidly, requiring intensive systemic therapies. The malignant non-Langerhans cell histiocytoses in general have a poor prognosis, here, complex chemotherapy protocols are usually applied, with inconsistant results. An interesting perspective in non-malignant rare histiocytoses might be small molecular inhibitors, in particular BRAF inhibitors, since BRAF mutations have been found in some subtypes of non-Langerhans cell histiocytoses. By prospective and retrospective collection of experiences in a new registry (the "International Rare Histiocytic Disorders Registry", IRHDR), knowledge about these rare diseases might hopefully be improved.

show abstract

Section: General Remarks and Clinical Presentationmentioning

confidence: 99%

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

show abstract

“…We were interested to read about the two cases of necrobiotic xanthogranuloma (NXG) recently reported in Clinical and Experimental Dermatology . Although both groups rightly note paraproteinaemia as the commonest systemic association, dermatologists should be wary of the myriad of potentially sight‐threatening ophthalmological manifestations of NXG, in addition to its proclivity towards periocular involvement …”

mentioning

confidence: 99%